GlassScriptPhysician profile
Karl T Schroeder
NPI 1003097114
$6,071.76
in general payments reported to CMS, 2019-2025
35 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $550 · 2021: $1,130 · 2022: $1,061 · 2023: $263 · 2024: $201 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.23 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,097.46 | 2019-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $784.88 | 2019-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $568.59 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.77 | 2019-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $353.72 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $342.57 | 2020-2025 | Acthar |
| Insmed, INC. | $317.12 | 2021-2025 | Arikayce |
| Electromed, INC. | $299.99 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $281.47 | 2019-2025 | Dupixent |
| Amgen INC. | $229.32 | 2020-2025 | Tezspire |
| Mallinckrodt Enterprises LLC | $174.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $137.16 | 2019-2022 | |
| Philips North America LLC | $123.33 | 2019-2025 | Vest Therapy Und |
| Baxter Healthcare | $101.84 | 2022 | |
| Csl Behring | $72.66 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $70.87 | 2019-2020 | |
| Viatris Specialty LLC | $66.76 | 2025 | Yupelri |
| Genzyme Corporation | $62.65 | 2019-2023 | |
| Advanced Respiratory, INC | $60.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.91 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $54.55 | 2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $42.22 | 2019-2022 | |
| Sandoz INC. | $35.83 | 2024 | Treprostinil |
| Gilead Sciences, INC. | $33.41 | 2023 | |
| Shire North American Group INC | $32.66 | 2019 | |
| Covidien LP | $30.84 | 2019 | |
| Apria Healthcare LLC | $28.13 | 2021 | |
| Verona Pharma, INC. | $23.49 | 2025 | Ohtuvayre |
| Inogen, INC. | $21.36 | 2022 | |
| Ethicon INC. | $20.95 | 2019 | |
| Medtronic, INC. | $20.88 | 2025 | Illumisite |
| Olympus America INC. | $19.72 | 2021 | |
| United Therapeutics Corporation | $17.90 | 2021 | |
| Eisai INC. | $15.46 | 2020 | |
| Veran Medical Technologies, INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.